Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Meropenem/Colistin Versus Meropenem/Ampicillin-Sulbactam in the Treatment of Carbapenem-Resistant Pneumonia Publisher Pubmed



Khalili H1 ; Shojaei L2 ; Mohammadi M3 ; Beigmohammadi MT3 ; Abdollahi A4 ; Doomanlou M5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Clinical Pharmacy, Faculty of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran
  3. 3. Department of Intensive Care Unit, Imam Khomeini Hospital, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Department of Pathology, Faculty of Medicine, Tehran University of Medical Sciences, Imam Khomeini Hospital, Tehran, Iran
  5. 5. Central Laboratory, Imam Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran

Source: Journal of Comparative Effectiveness Research Published:2018


Abstract

Aim: Efficacy of colistin and ampicillin-sulbactam have not been compared in treatment of ventilator-associated pneumonia due to A. baumannii. Efficacy of colistin and ampicillin-sulbactam in combination with meropenem were compared in treatment of ventilator-associated pneumonia due to carbapenem-resistant A. baumannii. Method: 47 patients with ventilator-associated pneumonia due to carbapenem-resistant A. baumannii were randomized to receive meropenem/colistin or meropenem/ampicillin-sulbactam for 14 days. Clinical and microbiological responses and 28-day mortality were considered as outcomes. Results: Clinical response (75 vs 69.6%; p = 0.75) and microbial eradication (87.50 vs 91.3%; p = 0.59) were comparable between meropenem/colistin and meropenem/ampicillin-sulbactam groups, respectively. Conclusion: In this study, clinical and microbiological response were comparable between the meropenem/colistin and meropenem/ampicillin-sulbactam groups. © 2018 Future Medicine Ltd.
Other Related Docs
11. First Report of Oxa-143-Lactamase Producing Acinetobacter Baumannii in Qom, Iran, Iranian Journal of Basic Medical Sciences (2017)
12. Colistin: Efficacy and Safety in Different Populations, Expert Review of Clinical Pharmacology (2015)
16. Distribution and Characteristics of Bacteria Isolated From Cystic Fibrosis Patients With Pulmonary Exacerbation, Canadian Journal of Infectious Diseases and Medical Microbiology (2022)